<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myxedema coma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myxedema coma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myxedema coma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myxedema coma is defined as severe hypothyroidism leading to decreased mental status, hypothermia, and other symptoms related to slowing of function in multiple organs. It is a medical emergency with a high mortality rate. Fortunately, it is now a rare presentation of hypothyroidism, likely due to earlier diagnosis as a result of the widespread availability of thyroid-stimulating hormone (TSH) assays.</p><p>Early recognition and therapy of myxedema coma are essential. Treatment should be initiated on the basis of clinical suspicion without waiting for laboratory results. Important clues to the possible presence of myxedema coma in a poorly responsive patient are the presence of a thyroidectomy scar or a history of radioiodine therapy or hypothyroidism. A history obtained from family members often reveals antecedent symptoms of thyroid dysfunction followed by progressive lethargy, stupor, and coma.</p><p>The clinical presentation, diagnosis, and treatment of myxedema coma will be reviewed here. The diagnosis and treatment of hypothyroidism are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">"Disorders that cause hypothyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The demographics of patients who develop myxedema coma are those of hypothyroidism in general, with older women being most often affected [<a href="#rid1">1</a>].</p><p>Myxedema coma can occur as the culmination of severe, longstanding hypothyroidism or be precipitated by an acute event in a poorly controlled hypothyroid patient, such as infection, myocardial infarction, cold exposure, surgery [<a href="#rid2">2</a>], or the administration of sedative drugs, especially opioids. It can occur in patients who have any of the usual causes of hypothyroidism (particularly chronic autoimmune thyroiditis) because its insidious course may lead the diagnosis to be overlooked, compared with postsurgical or postablative hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">"Disorders that cause hypothyroidism"</a>.)</p><p>Myxedema coma can occur in patients with central hypothyroidism, lithium-induced hypothyroidism [<a href="#rid3">3,4</a>], iodinated radiocontrast-induced hypothyroidism [<a href="#rid5">5</a>], or checkpoint inhibitor (<a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>)-induced hypothyroidism [<a href="#rid6">6</a>], and there are a dozen case reports of myxedema coma in patients taking <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid7">7</a>]. In a retrospective study of 82 patients admitted to 32 French intensive care units (ICUs), 54 percent did not have a prior known diagnosis of hypothyroidism, and precipitating events included discontinuing thyroid hormone (28 percent), sepsis (15 percent), and amiodarone (11 percent) [<a href="#rid8">8</a>]. Mortality in the ICU was 26 percent.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The hallmarks of myxedema coma are decreased mental status and hypothermia, but hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation are often present as well (<a class="graphic graphic_table graphicRef54836" href="/z/d/graphic/54836.html" rel="external">table 1</a>). Puffiness of the hands and face, a thickened nose, swollen lips, and an enlarged tongue may occur secondary to nonpitting edema with abnormal deposits of albumin and mucin in the skin and other tissues (myxedema).</p><p>A patient may also have clinical manifestations of the acute event that precipitated myxedema coma (eg, infection, myocardial infarction). Notably, a patient with infection may not have a febrile response due to loss of thyroid-hormone mediated thermogenesis. (See <a class="local">'Hypothermia'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Neurologic manifestations</span><span class="headingEndMark"> — </span>Despite the name myxedema coma, patients frequently do not present in coma but do manifest lesser degrees of altered consciousness [<a href="#rid8">8,9</a>]. This usually takes the form of confusion with lethargy and obtundation. Alternatively, a more activated presentation may occur with prominent psychotic features, so-called myxedema madness [<a href="#rid10">10,11</a>]. Untreated, patients will progress to coma.</p><p>Focal or generalized seizures may occur, sometimes due to concomitant hyponatremia, and status epilepticus has been reported [<a href="#rid12">12,13</a>]. In the absence of seizures, electroencephalogram (EEG) findings are nonspecific with slowing and decreased amplitude, rarely with triphasic waves [<a href="#rid14">14</a>]. When cerebrospinal fluid is obtained (usually to rule out infection in a patient with fever and mental status changes), modest elevation of protein levels (&lt;100 mg/dL) may be seen [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Hyponatremia</span><span class="headingEndMark"> — </span>Hyponatremia is present in approximately one-half of patients with myxedema coma. It can be severe and may contribute to the decrease in mental status. Most, but not all, patients have an impairment in free water excretion due to inappropriate excess vasopressin secretion or impaired renal function [<a href="#rid15">15,16</a>]. In addition, some patients may have concomitant adrenal insufficiency. (See <a class="local">'Laboratory evaluation'</a> below and <a class="local">'Glucocorticoids'</a> below.)</p><p>The low serum sodium concentration is reversible after treatment of the hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults", section on 'Hypothyroidism'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hypothermia</span><span class="headingEndMark"> — </span>Hypothermia is present in many patients with myxedema coma (<a class="graphic graphic_table graphicRef54836" href="/z/d/graphic/54836.html" rel="external">table 1</a>). It is due to the loss of thyroid hormone-mediated thermogenesis that accompanies the decrease in metabolism.</p><p>The low body temperature may not be recognized initially, because many automatic thermometers do not register frankly hypothermic body temperatures. If a low temperature is found, the thermometer itself should be checked to avoid an incorrect measurement. The severity of the hypothermia is related to mortality in severe hypothyroidism; the lower the temperature, the more likely a patient is to die.</p><p class="headingAnchor" id="H7"><span class="h2">Hypoventilation</span><span class="headingEndMark"> — </span>Hypoventilation with respiratory acidosis results primarily from central depression of ventilatory drive with decreased responsiveness to hypoxia and hypercapnia [<a href="#rid17">17</a>]. Other contributing factors include respiratory muscle weakness, mechanical obstruction by a large tongue, and sleep apnea. (See  <a class="medical medical_review" href="/z/d/html/7865.html" rel="external">"Respiratory function in thyroid disease", section on 'Hypothyroidism'</a>.)</p><p>Some patients require mechanical ventilation (see  <a class="medical medical_review" href="/z/d/html/5112.html" rel="external">"Control of ventilation"</a>). Airway management may be complicated by myxedematous infiltration of the pharynx [<a href="#rid18">18</a>]. Recovery from ventilatory depression may take as long as three to six months after treatment of hypothyroidism [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>Hypoglycemia may be caused by hypothyroidism alone or, more often, by concurrent adrenal insufficiency due to autoimmune adrenal disease or hypothalamic-pituitary disease. The presumed mechanism is decreased gluconeogenesis, but starvation and infection can contribute. (See  <a class="medical medical_review" href="/z/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Cardiovascular abnormalities</span><span class="headingEndMark"> — </span>Thyroid hormone plays a role in blood pressure homeostasis. Hypothyroid patients have diastolic hypertension, even though cardiac output is reduced, and a narrowed pulse pressure. Severe hypothyroidism is associated with bradycardia, decreased myocardial contractility, a low cardiac output, and sometimes hypotension [<a href="#rid19">19</a>]. Overt congestive heart failure is quite rare in the absence of preexisting cardiac disease. This is probably due to the lower tissue demands for oxygenation and cardiac output in hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7852.html" rel="external">"Cardiovascular effects of hypothyroidism"</a>.)</p><p>Pericardial effusion may be present. Its clinical manifestations include diminished heart sounds, low voltage on electrocardiogram (ECG), and a large cardiac silhouette on chest radiograph; however, ventricular function is rarely compromised. (See  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis"</a>.)</p><p>All of the cardiac abnormalities are reversible with thyroid hormone therapy [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of myxedema coma is initially based upon the history, physical examination, and exclusion of other causes of coma (see  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults", section on 'Evaluation'</a>). In patients in whom the diagnosis is suspected, thyroid function tests showing hypothyroidism support the diagnosis.</p><p class="headingAnchor" id="H2568757856"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of myxedema coma should be considered in any patient with coma or depressed mental status who also has hypothermia, hyponatremia, and/or hypercapnia [<a href="#rid8">8,9</a>] (see <a class="local">'Clinical presentation'</a> above). Important clues to the possible presence of myxedema coma in a poorly responsive patient are the presence of a thyroidectomy scar or a history of radioiodine therapy or hypothyroidism. A history obtained from family members often reveals antecedent symptoms of thyroid dysfunction followed by progressive lethargy, stupor, and coma. There is no single test that confirms the diagnosis with certainty, and the symptoms caused by potential precipitating events (eg, sepsis) can overlap with the symptoms of myxedema coma.</p><p class="headingAnchor" id="H2604676597"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>If the diagnosis of myxedema coma is suspected, a blood sample should be drawn prior to treatment for measurement of:</p><p class="bulletIndent1"><span class="glyph">●</span>TSH</p><p class="bulletIndent1"><span class="glyph">●</span>Free thyroxine (T4)</p><p class="bulletIndent1"><span class="glyph">●</span>Cortisol</p><p></p><p>The serum T4 concentration is usually very low. The serum TSH concentration may be high (indicating primary hypothyroidism) or it may be low, normal, or slightly high (indicating central hypothyroidism). Most patients with myxedema coma have primary hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism", section on 'Diagnosis'</a>.)</p><p>Patients with central hypothyroidism may have associated hypopituitarism and secondary adrenal insufficiency. Furthermore, the pituitary corticotropin (ACTH) response to stress may be impaired in severe hypothyroidism [<a href="#rid21">21</a>]. In addition, patients with autoimmune-mediated primary hypothyroidism may have concomitant primary adrenal insufficiency. Ideally, cortisol should be measured before and after cosyntropin administration. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'ACTH stimulation tests'</a> and  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>A diagnostic scoring system for myxedema coma has been proposed based on 21 patients diagnosed with myxedema coma [<a href="#rid22">22</a>]. The scoring system gives points for the degree of hypothermia; lethargy, obtundation, stupor, or coma; anorexia, reduced intestinal mobility, or paralytic ileus; the presence of a precipitating event; the degree of bradycardia, electrocardiogram (ECG) changes, pericardial or pleural effusions, cardiomegaly or hypertension; and hyponatremia, hypoglycemia, hypoxemia, hypercapnia, or reduced glomerular filtration rate (GFR). Although some clinicians may find this scoring system useful, it is limited by the small number of patients from which it was derived.</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>If myxedema coma is suspected, treatment should be instituted without waiting for laboratory confirmation. Myxedema coma is an endocrine emergency that should be managed aggressively as the mortality rate remains high, even with treatment. (See <a class="local">'Prognosis'</a> below.)</p><p>Patients require simultaneous treatment with the following (<a class="graphic graphic_table graphicRef61507" href="/z/d/graphic/61507.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Supportive measures</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids (until the possibility of coexisting adrenal insufficiency has been excluded)</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid hormone</p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate management of coexisting problems (eg, infection)</p><p></p><p class="headingAnchor" id="H2075158515"><span class="h2">Supportive measures</span><span class="headingEndMark"> — </span>Supportive measures are extremely important in the treatment of patients with myxedema coma and, in the first day or so, may make the difference between survival and death. These measures include treatment in an intensive care unit (ICU), mechanical ventilation if necessary, judicious administration of intravenous fluids including electrolytes and glucose, correction of hypothermia, and treatment of any underlying infection. (See <a class="local">'Clinical presentation'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Dilute fluids should be avoided in hyponatremic patients to prevent a further reduction in the plasma sodium concentration. (See <a class="local">'Monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">"Overview of the treatment of hyponatremia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension, if present and not caused by volume depletion, will be corrected by thyroid hormone therapy over a period of hours to days. Severe hypotension that does not respond to fluids should be treated with a vasopressor drug until the <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> has had time to act. (See  <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Initial approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Passive rewarming with a blanket is preferred for correction of hypothermia. Active rewarming carries a risk of vasodilatation and worsening hypotension. (See  <a class="medical medical_review" href="/z/d/html/6598.html" rel="external">"Hypothermia in children: Management"</a> and  <a class="medical medical_review" href="/z/d/html/178.html" rel="external">"Accidental hypothermia in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with any critically ill, comatose patient, empiric administration of antibiotics should be considered until appropriate cultures are proven negative.</p><p></p><p class="headingAnchor" id="H318236648"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Until the possibility of coexisting adrenal insufficiency has been excluded, the patient must be treated with glucocorticoids in stress doses (eg, <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> given intravenously, 100 mg every eight hours). (See  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p>Patients with central hypothyroidism may have associated hypopituitarism and secondary adrenal insufficiency. In addition, patients with autoimmune-mediated primary hypothyroidism may have concomitant primary adrenal insufficiency. Also, pituitary corticotropin (ACTH) secretion may be blunted in severe hypothyroidism, resulting in subnormal cortisol response to stress [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Thyroid hormone</span></p><p class="headingAnchor" id="H4198180475"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>For patients with myxedema coma, we suggest combined therapy with <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> and <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> rather than levothyroxine alone (<a class="graphic graphic_table graphicRef61507" href="/z/d/graphic/61507.html" rel="external">table 2</a>). We prefer to give both hormones because the biologic activity of triiodothyronine (T3) is greater, and its onset of action is more rapid than T4 [<a href="#rid23">23</a>]. Proper dosing of liothyronine is important, however, and high serum concentrations should be avoided (see <a class="local">'Dosing'</a> below). The conversion of T4 to T3 is impaired due to both hypothyroidism and any concurrent nonthyroidal illness. This decrease in T4 to T3 conversion may be a protective adaptation in the face of severe illness (see  <a class="medical medical_review" href="/z/d/html/7837.html" rel="external">"Thyroid hormone synthesis and physiology", section on 'Regulation of extrathyroidal T3 production'</a>). The optimal mode of thyroid hormone therapy in patients with myxedema coma is controversial, largely because the condition is so rare that there are no clinical trials comparing the efficacy of different treatment regimens. Whether patients with myxedema coma should be treated with levothyroxine, liothyronine, or both is uncertain [<a href="#rid9">9</a>]. Some experts favor administration of liothyronine, while others favor levothyroxine, preferring that T3 production be governed by the activity of 5'-deiodinase in the patient, while others prefer a combination of levothyroxine and liothyronine [<a href="#rid9">9,24-28</a>].</p><p class="headingAnchor" id="H4279037429"><span class="h3">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">Levothyroxine</a> and <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> should be given intravenously as a slow bolus, when available, because gastrointestinal absorption may be impaired [<a href="#rid24">24,25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levothyroxine</strong> – We typically administer an initial dose of 200 to 400 mcg <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> intravenously, followed by daily intravenous doses of 50 to 100 mcg until the patient can take oral levothyroxine. The lower end of the dosing range is preferred in lighter and older patients and in those at risk for cardiac complications (myocardial infarction, arrhythmia). This regimen should raise the total serum T4 level by 2 to 4 mcg/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liothyronine</strong> – We administer intravenous <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> at the same time; the initial dose is 5 to 20 mcg, followed by 2.5 to 10 mcg every eight hours, with lower doses chosen for older patients and those with coexisting cardiovascular disease. Liothyronine is continued until there is clinical improvement and the patient is stable. Excessive replacement with liothyronine should be avoided. In one small study, high serum triiodothyronine levels during therapy were associated with mortality [<a href="#rid29">29</a>]. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p>The optimal dose of thyroid hormone therapy in patients with myxedema coma is uncertain. Both very high (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> &gt;500 mcg, <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> ≥75 mcg) and very low doses seem less effective than intermediate doses [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2709748695"><span class="h2">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular</strong> – Increasing serum thyroid hormone concentrations rapidly carries some risk of precipitating myocardial infarction or atrial arrhythmias. Patients should be treated in an ICU with continuous electrocardiogram (ECG) monitoring.</p><p></p><p class="bulletIndent1">While increasing serum thyroid hormone concentrations rapidly carries some risk of precipitating myocardial infarction or atrial arrhythmias, this risk must be accepted because of the high mortality of untreated myxedema coma. In one randomized trial of 11 patients, those who received a 500 mcg loading dose of <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>, followed by 100 mcg daily, had a lower mortality than those treated with 100 mcg daily without a loading dose (one of six died compared with three of five who did not receive the loading dose); however, the difference did not reach statistical significance [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyponatremia</strong> – Patients with hyponatremia require monitoring of fluids and electrolytes. To the extent that hyponatremia is due to hypothyroidism, it will slowly correct with thyroid hormone replacement, and if hyponatremia is mild, other measures may not be needed [<a href="#rid16">16,32</a>]. Since the precipitating cause of or complications from myxedema may also be contributing to hyponatremia, patients with sodium &lt;130 mEq/L require a comprehensive evaluation and may need treatment with hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, fluid restriction, or other measures. (See  <a class="medical medical_review" href="/z/d/html/2350.html" rel="external">"Overview of the treatment of hyponatremia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid tests</strong> – Serum T4 (or free T4) and T3 should be measured every one to two days to confirm that the therapy is working and that very high levels of T3 are avoided. Due to its pharmacokinetics, serum T3 levels may be above the reference range if measured within an hour after intravenous administration. Therefore, in patients receiving parenteral <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> therapy, serum T3 should be measured at least one hour after dosing [<a href="#rid23">23,33</a>].</p><p></p><p class="bulletIndent1">Optimal levels for serum TSH, T4, and T3 are not established for the treatment of myxedema coma [<a href="#rid25">25</a>]. Serum TSH typically falls at a rate of approximately 50 percent per week in hypothyroid patients receiving a full replacement dose of thyroid hormone. Therefore, failure of the serum TSH to fall is an indication of inadequate therapy. High serum T3 levels warrant an immediate reduction in <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a>. The decrement in dose depends on the degree of T3 elevation.</p><p></p><p>Clinical and biochemical improvement are typically evident within a week. Once there is improvement (regained consciousness, able to swallow oral medications, improved mental status, improved pulmonary and cardiac function), the patient can be treated with oral <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> alone. The initial oral levothyroxine dose should be determined based on body weight, age, coexistent cardiovascular disease, and the recent intravenous dose (note that only 75 to 80 percent of an oral dose is absorbed when converting from an intravenous to an oral dose under steady state conditions, but the intravenous dose given in the early treatment of myxedema coma is unlikely to reflect steady state conditions). Treatment of hypothyroidism is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Dose and monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1380119682"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Myxedema coma is an endocrine emergency that should be managed aggressively as the mortality rate is high, ranging from 30 to 50 percent [<a href="#rid1">1,8,29,34,35</a>]. In a report of 149 Japanese patients with myxedema coma, the mortality rate was 30 percent [<a href="#rid1">1</a>]. Older age, cardiac complications, reduced consciousness, need for mechanical ventilation, persistent hypothermia, and sepsis were predictive of mortality [<a href="#rid1">1,30,34</a>]. Some patients have a complete recovery [<a href="#rid13">13,36</a>].</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Myxedema coma is defined as severe hypothyroidism leading to slowing of function in multiple organs. It is a medical emergency with a high mortality rate. Fortunately, it is now a rare presentation of hypothyroidism, likely due to earlier diagnosis, as a result of the widespread availability of thyroid-stimulating hormone (TSH) assays. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The hallmarks of myxedema coma are decreased mental status and hypothermia, but hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation are often present as well (<a class="graphic graphic_table graphicRef54836" href="/z/d/graphic/54836.html" rel="external">table 1</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – If the diagnosis of myxedema coma is suspected, a blood sample should be drawn for measurement of serum thyroxine (T4), TSH, and cortisol (ideally before and after cosyntropin administration) before therapy with a glucocorticoid and thyroid hormone is initiated. The serum T4 concentration is usually very low. The serum TSH concentration may be high (indicating primary hypothyroidism) or it may be low, normal, or slightly high (indicating central hypothyroidism). (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Patients with myxedema coma should be treated aggressively (<a class="graphic graphic_table graphicRef61507" href="/z/d/graphic/61507.html" rel="external">table 2</a>) because the mortality rate approaches 40 percent. In circumstances where laboratory confirmation of hypothyroidism is delayed, treatment with thyroid hormone and glucocorticoids should be instituted without waiting for laboratory confirmation. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive measures</strong> – Supportive measures are extremely important, including mechanical ventilation, appropriate fluid replacement, and correction of hyponatremia and hypothermia. In addition, there is often an associated illness that must be treated, such as infection or gastrointestinal bleeding. (See <a class="local">'Supportive measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – Until coexisting adrenal insufficiency can be excluded, the patient should be given high-dose glucocorticoid therapy (<a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 100 mg intravenously every eight hours for two days, then lower doses). (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thyroid hormone</strong> – For patients with myxedema coma, we suggest combined therapy with <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> and <a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a> rather than levothyroxine alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest an initial dose of 200 to 400 mcg levothyroxine intravenously, followed by daily intravenous doses of 50 to 100 mcg until the patient can take oral levothyroxine. Liothyronine is given intravenously at the same time; the initial dose is 5 to 20 mcg, followed by 2.5 to 10 mcg every eight hours, depending upon the patient's age and coexisting cardiovascular disease, with lower doses chosen for older patients and those with coexisting cardiovascular disease. Liothyronine is continued until there is clinical improvement and the patient is stable. (See <a class="local">'Treatment'</a> above and <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients should be monitored for cardiac arrhythmias, for correction of hyponatremia (if present), and for improvement in thyroid tests. Serum T4 (or free T4) and T3 should be measured every one to two days to confirm that the therapy is working and that very high levels of T3 are avoided. Serum TSH typically falls at a rate of approximately 50 percent per week in hypothyroid patients receiving a full replacement dose of thyroid hormone. Therefore, failure of the serum TSH to fall is an indication of inadequate therapy. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Myxedema coma is associated with a high mortality rate (30 to 50 percent). Older age, cardiac complications, reduced consciousness, need for mechanical ventilation, persistent hypothermia, and sepsis are predictive of mortality. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ono Y, Ono S, Yasunaga H, et al. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. J Epidemiol 2017; 27:117.</a></li><li><a class="nounderline abstract_t">Yafit D, Carmel-Neiderman NN, Levy N, et al. Postoperative myxedema coma in patients undergoing major surgery: Case series. Auris Nasus Larynx 2019; 46:605.</a></li><li><a class="nounderline abstract_t">Santiago R, Rashkin MC. Lithium toxicity and myxedema coma in an elderly woman. J Emerg Med 1990; 8:63.</a></li><li><a class="nounderline abstract_t">Waldman SA, Park D. Myxedema coma associated with lithium therapy. Am J Med 1989; 87:355.</a></li><li><a class="nounderline abstract_t">Tng EL, Aung AT, Chong N. Myxedema Coma Precipitated by Iohexol: Case Report and Brief Literature Review on the Wolff-Chaikoff Effect. Thyroid 2022; 32:739.</a></li><li><a class="nounderline abstract_t">Gummalla S, Manjunath M, Phillips B. Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab. Case Rep Endocrinol 2020; 2020:8855943.</a></li><li><a class="nounderline abstract_t">Hawatmeh A, Thawabi M, Abuarqoub A, Shamoon F. Amiodarone induced myxedema coma: Two case reports and literature review. Heart Lung 2018; 47:429.</a></li><li><a class="nounderline abstract_t">Bourcier S, Coutrot M, Ferré A, et al. Critically ill severe hypothyroidism: a retrospective multicenter cohort study. Ann Intensive Care 2023; 13:15.</a></li><li><a class="nounderline abstract_t">Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med 2007; 22:224.</a></li><li><a class="nounderline abstract_t">Westphal SA. Unusual presentations of hypothyroidism. Am J Med Sci 1997; 314:333.</a></li><li><a class="nounderline abstract_t">Mavroson MM, Patel N, Akker E. Myxedema Psychosis in a Patient With Undiagnosed Hashimoto Thyroiditis. J Am Osteopath Assoc 2017; 117:50.</a></li><li><a class="nounderline abstract_t">Jansen HJ, Doebé SR, Louwerse ES, et al. Status epilepticus caused by a myxoedema coma. Neth J Med 2006; 64:202.</a></li><li><a class="nounderline abstract_t">Fjølner J, Søndergaard E, Kampmann U, Nielsen S. Complete recovery after severe myxoedema coma complicated by status epilepticus. BMJ Case Rep 2015; 2015.</a></li><li><a class="nounderline abstract_t">Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol 1993; 240:333.</a></li><li><a class="nounderline abstract_t">Iwasaki Y, Oiso Y, Yamauchi K, et al. Osmoregulation of plasma vasopressin in myxedema. J Clin Endocrinol Metab 1990; 70:534.</a></li><li><a class="nounderline abstract_t">Liamis G, Filippatos TD, Liontos A, Elisaf MS. MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. Eur J Endocrinol 2017; 176:R15.</a></li><li><a class="nounderline abstract_t">Zwillich CW, Pierson DJ, Hofeldt FD, et al. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.</a></li><li><a class="nounderline abstract_t">Lee CH, Wira CR. Severe angioedema in myxedema coma: a difficult airway in a rare endocrine emergency. Am J Emerg Med 2009; 27:1021.e1.</a></li><li><a class="nounderline abstract_t">Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990; 88:631.</a></li><li><a class="nounderline abstract_t">Shenoy MM, Goldman JM. Hypothyroid cardiomyopathy: echocardiographic documentation of reversibility. Am J Med Sci 1987; 294:1.</a></li><li><a class="nounderline abstract_t">Bigos ST, Ridgway EC, Kourides IA, Maloof F. Spectrum of pituitary alterations with mild and severe thyroid impairment. J Clin Endocrinol Metab 1978; 46:317.</a></li><li><a class="nounderline abstract_t">Popoveniuc G, Chandra T, Sud A, et al. A diagnostic scoring system for myxedema coma. Endocr Pract 2014; 20:808.</a></li><li><a class="nounderline abstract_t">Ladenson PW, Goldenheim PD, Ridgway EC. Rapid pituitary and peripheral tissue responses to intravenous L-triiodothyronine in hypothyroidism. J Clin Endocrinol Metab 1983; 56:1252.</a></li><li><a class="nounderline abstract_t">HOLVEY DN, GOODNER CJ, NICOLOFF JT, DOWLING JT. TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE. Arch Intern Med 1964; 113:89.</a></li><li><a class="nounderline abstract_t">Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 2014; 24:1670.</a></li><li><a class="nounderline abstract_t">MacKerrow SD, Osborn LA, Levy H, et al. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med 1992; 117:1014.</a></li><li><a class="nounderline abstract_t">Arlot S, Debussche X, Lalau JD, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med 1991; 17:16.</a></li><li class="breakAll">Wartofsky L. Myxedema coma. In: The Thyroid: A Fundamental and Clinical Text, Braverman LE, Utiger RD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2000. p.843.</li><li><a class="nounderline abstract_t">Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh) 1985; 108:65.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 1999; 9:1167.</a></li><li><a class="nounderline abstract_t">Rodríguez I, Fluiters E, Pérez-Méndez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol 2004; 180:347.</a></li><li><a class="nounderline abstract_t">Maharjan G, Yadav MK, Khati N, et al. Hypothyroidism Induced Hyponatremia: A Case Report. JNMA J Nepal Med Assoc 2022; 60:815.</a></li><li><a class="nounderline abstract_t">Zaninovich AA, el Tamer E, el Tamer S, et al. Multicompartmental analysis of triiodothyronine kinetics in hypothyroid patients treated orally or intravenously with triiodothyronine. Thyroid 1994; 4:285.</a></li><li><a class="nounderline abstract_t">Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care 2008; 12:R1.</a></li><li><a class="nounderline abstract_t">Beynon J, Akhtar S, Kearney T. Predictors of outcome in myxoedema coma. Crit Care 2008; 12:111.</a></li><li><a class="nounderline abstract_t">Salomo LH, Laursen AH, Reiter N, Feldt-Rasmussen U. Myxoedema coma: an almost forgotten, yet still existing cause of multiorgan failure. BMJ Case Rep 2014; 2014.</a></li></ol></div><div id="topicVersionRevision">Topic 7822 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28142035" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30454972" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Postoperative myxedema coma in patients undergoing major surgery: Case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191030" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lithium toxicity and myxedema coma in an elderly woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2773973" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Myxedema coma associated with lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35180827" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myxedema Coma Precipitated by Iohexol: Case Report and Brief Literature Review on the Wolff-Chaikoff Effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33145114" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29793782" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amiodarone induced myxedema coma: Two case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36892784" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Critically ill severe hypothyroidism: a retrospective multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712058" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myxedema coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9365336" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Unusual presentations of hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055088" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Myxedema Psychosis in a Patient With Undiagnosed Hashimoto Thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16788220" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Status epilepticus caused by a myxoedema coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25809434" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complete recovery after severe myxoedema coma complicated by status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336171" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reversibility of dementia in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2298864" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Osmoregulation of plasma vasopressin in myxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27484454" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1113761" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ventilatory control in myxedema and hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19857436" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe angioedema in myxedema coma: a difficult airway in a rare endocrine emergency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189307" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thyroid hormone and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605187" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypothyroid cardiomyopathy: echocardiographic documentation of reversibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/108289" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spectrum of pituitary alterations with mild and severe thyroid impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518183" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A diagnostic scoring system for myxedema coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6841560" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapid pituitary and peripheral tissue responses to intravenous L-triiodothyronine in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14067598" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266247" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1443970" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2037720" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2037720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969812" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of myxoedema coma--factors associated with fatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10646654" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Factors associated with mortality of myxedema coma: report of eight cases and literature survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14765987" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36705139" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypothyroidism Induced Hyponatremia: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833665" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Multicompartmental analysis of triiodothyronine kinetics in hypothyroid patients treated orally or intravenously with triiodothyronine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173846" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Predictors of outcome in myxoedema coma: a study from a tertiary care centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254932" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictors of outcome in myxoedema coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481020" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Myxoedema coma: an almost forgotten, yet still existing cause of multiorgan failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
